FY25 sbir phase III - nvasive: unraveling the enigma of metastasis
Active Definitive Contract Awarded Last action
- Contract number
- 80NSSC25CA074
- Awardee
-
Encapsulate Inc. UEI JKQNFNJWF175
- Awarding agency
-
Shared Services Center
National Aeronautics and Space Administration
- Obligated
- $4,477,527
Award facts
- Contract value 86% obligated
- $5,217,527.00 Current and potential, with all options
- Completion date 48% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 500 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Farmington, CT 06032, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $3,247,527 | |
| Additional Work (new agreement, FAR part 6 applies) | $300,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $440,000 | |
| Original award | $490,000 |
About this award
The NASA Shared Services Center awarded a $5,217,527 definitive contract to Encapsulate Inc. for FY25 SBIR Phase III development under the NVASIVE project on May 23, 2025, under a total small business set-aside.
Encapsulate Inc. is a self-certified small disadvantaged business based in Farmington, Connecticut. The contract is firm fixed price with an ultimate completion date of May 22, 2028. Work is performed at Encapsulate Inc.'s Farmington, CT facility.
The originating solicitation funds NVASIVE: Unraveling the Enigma of Metastasis, which applies artificial intelligence and machine learning to predict metastasis using noninvasive techniques and microgravity research environments. The project develops automated microfluidic biochip platforms integrated with bioreactors and 3D tumor models designed to test patient-derived cancer cells against chemotherapy drugs, enabling personalized treatment selection prior to therapy initiation. The technology targets colorectal and pancreatic cancers, addressing the challenge that over 70 percent of cancer patients undergo ineffective chemotherapy through trial-and-error methods.
This Phase III award follows Encapsulate's Phase I contract ($156,494, completed February 6, 2025) and Phase II contract ($899,787, scheduled completion July 15, 2027), all designated as total small business set-asides under the SBIR program.
Quick answers
Who was awarded contract 80NSSC25CA074?
80NSSC25CA074 was awarded to Encapsulate Inc. by Shared Services Center (National Aeronautics and Space Administration) on May 23, 2025.
How much is contract 80NSSC25CA074 worth?
The government has obligated $4,477,527 on 80NSSC25CA074. Its current value, with exercised options, is $5,217,527.
Was contract 80NSSC25CA074 competed?
The extent of competition for 80NSSC25CA074 was full and open competition after exclusion of sources. The government received 500 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award